Investors & Media International Stem Cell Corporation to Present Interim Clinical Results at the American Academy of Neurology International Stem Cell Corporation Announces 2017 Fourth Quarter and Year-End Results International Stem Cell Corporation Completes Dosing Of Second Cohort In Parkinson's Disease Clinical Trial International Stem Cell Corporation is Valued at $33 Million Market Value by Edison Investment Research International Stem Cell Corporation Treated Real Estate Icon Kevin Weeks International Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinson's Disease International Stem Cell Corporation Announces Operating Results for the Three and Nine-Months ended September 30, 2017 International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson's Disease Clinical Trial International Stem Cell Corporation to Present Six-Month Results of Neural Stem Cell Transplantation for Parkinson's Disease at Neuroscience 2017 International Stem Cell Corporation Receives Key Stem Cell Patent in Australia 1 2 3 4 5 6 7 8 9 << < > >>
